Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Napabucasin plus FOLFIRI in previously treated metastatic colorectal cancer
NCT02753127Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Jun 2016
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of napabucasin in metastatic colorectal cancer (mCRC), sponsored by Sumitomo Pharma America. Started Jun 2016; status: completed.
02
Drugs
napabucasin
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02753127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02753127.